BRIEF—Boehringer pens peptide-led drug discovery deal with 3B Pharmaceuticals

Privately-held German companies Boehringer Ingelheim and 3B Pharmaceuticals have signed a multi-year collaboration in peptide-led drug discovery.

Boehringer will nominate a set of molecular disease targets on which 3BP will employ its high-diversity peptide library and hit identification technology.

Hit compounds identified will be further optimized and jointly characterized by both companies.

Financial terms of the collaboration were not disclosed.